ClinicalTrials.gg
Sign In

Drug

Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 clinical trials

Also written INCA33890.

studies test it
3
open now
3
in phase 3
1
first study started
2026

Keep track of what changes. Save the Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

INCA33890
3

By phase

A phase 1/2 study counts in both.

Phase 2
2
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Colorectal Neoplasms
2

Who runs them

Industry 2 · Other 1

Incyte Corporation (2) · Groupe Oncologie Radiotherapie Tete et Cou (1)

Studies

Open first, then newest update. How each study uses Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 is read from its arms, and is right about nine times in ten.

Testing it · 3

Given in every arm · 2 — Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890 is usual care beside what is tested